IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.05
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.046

21 Feb
2025

-0.001

OPEN

$0.05

-2.13%

HIGH

$0.05

834,156

LOW

$0.05

TARGET
$0.145 215.2% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.0 - 0.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.3 M
Book Value Per Share xxxxxxxxxxxxxxx2.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.8 M
Net Profit Margin xxxxxxxxxxxxxxx-191.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-38.95 %
Return on Invested Capital xxxxxxxxxxxxxxx-38.21 %
Return on Assets xxxxxxxxxxxxxxx-34.20 %
Return on Equity xxxxxxxxxxxxxxx-38.95 %
Return on Total Capital xxxxxxxxxxxxxxx-46.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx3.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.1 M
Capex % of Sales xxxxxxxxxxxxxxx30.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

03/02/2025

1

Speculative Buy

$0.12

160.87%

ImpediMed’s 2Q result was mixed, according to Ord Minnett, with revenue of $3.3m, free cash flow of -$2.6m, and payor coverage of 259m lives exceeding expectations, while US SOZO sales fell short at 20 units versus 28 in the first quarter.

The broker remains encouraged by ongoing lead pipeline growth, expanding private payor coverage, and strong pricing tailwinds, but awaits a clearer acceleration in US sales.

Key near-term catalysts include contract wins and material payor updates, suggest the analysts. The target price is lowered to 12c from 13c, with a Speculative Buy rating retained.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.80 cents.
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

28/10/2024

1

Speculative Buy

$0.09

95.65%

ImpediMed reported 1Q25 revenue of $2.7m, down -7% quarter-on-quarter, with lower Rest of World sales and an FX impact contributing to the decline.

Canaccord Genuity observes the company added 22 new Sozo units in the US, but device churn limited the active installed base increase to just 17 units globally, bringing the total to 1,022.

The company’s core annual recurring revenue remains steady at $11.6m. Cash outflows from operations totaled -$4.8m, with management expecting improvement in the coming quarter as cost rationalisation efforts take effect.

The broker highlights the company holds $18.6m in cash, which should be sufficient for near-term commercialisation efforts. Speculative Buy rating retained with a price target of $0.09. No major updates were made to financial forecasts.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.10 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Rudi’s View: Earnings Optimism On The Rise

Feb 05 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Feb 05, 2025

Feb 05 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Oct 28, 2024

Oct 28 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 26, 2024

Sep 26 2024 - Daily Market Reports
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 13-09-24

Sep 13 2024 - Weekly Reports

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps